Hard to believe? Well, a new ranking suggests the Swiss drugmaker will become the biggest of the big by 2014 thanks to "surging" demand for various its cancer meds, such Avastin, Mircera and Herceptin, according to
EvaluatePharma, adding that buying up all of Genentech would only solidify its position.
The big loser? Pfizer, not surprisingly, since it faces patent expirations on so many big drugs, namely Lipitor, Norvasc and Viagra. We realize, by the way, that this list has been circulating for a couple of days, but we enjoy speculation as much as anyone.
2 Comments
If you look at HOW they calculated this table, their logic is ridiculously flawed. And, although I don't completely disagree with their Top 10, I think its not quite bulletproof.
We all have been trained not to look too far down the road for predictable outcomes in drug research, approval and commercial longevity. 2014 might as well be 2041 for the sake of this report.
Just consider a similar list for biotechnology companies not too many years back with Amgen, Genentech, Chiron & Immunex leading the list. 75% of those "industry stalwarts" are likely to be gone before the beginning of next year, absorbed into much larger entities. And who would have predicted the rapid emergence of companies like Gilead & Celgene. Five years ago, neither was even on the map.
Fun to debate, but not of much use in reality, in my opinion.
That list is ridiculous. Pfizer will remain #1 by buying up as many companies as it needs to stay #1.